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Abstract
Background: The objective of this study was to evaluate the effect of platinum-based drugs on nuclear-factor
erythroid2 like 2 (NRF2) signaling in non-small cell lung cancer cell lines with or without Kelch-like ECH-associated
protein 1 (KEAP1) mutations and to determine the role of NRF2 and KEAP1 on platinum-based drug treatment.
Methods: We used real-time PCR to assess relative mRNA expression and used western blotting and
immunofluorescence assays to assess protein expression. Small interfering RNA and shuttle plasmids were used to
modulate the expression of NRF2, wild-type KEAP1, and mutant KEAP1. Drug sensitivity to platinum-based drugs
was evaluated with Cell Count Kit-8.
Results: We found that platinum-based therapies modified the NRF2 signaling pathway differently in KEAP1-
mutated non-small cell lung cancer (NSCLC) cell lines compared with wild-type KEAP1 cell lines. The reactive
degree of NRF2 signaling also varies between nedaplatin and cisplatin. The modification of NRF2 or KEAP1
expression in NSCLC cell lines disrupted downstream gene expression and cell sensitivity to platinum-based drugs.
Finally, gene expression data retrieved from The Cancer Genome Atlas (TCGA) consortium indicated that KEAP1
mutation significantly affects NRF2 signaling activity in patients with NSCLC.
Conclusions: Our findings suggest that NRF2 signaling plays an indispensable role in NSCLC cell sensitivity to
platinum-based treatments and provides a rationale for using NRF2 as a specific biomarker for predicting which
patients will be most likely to benefit from platinum-based treatment.
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Background
Non-small cell lung cancer (NSCLC) is associated with
considerably high mortality worldwide [1]. Surgery
can ensure local disease control in patients with early
stages of disease, and patients unsuitable for surgery
at diagnosis, primarily those with advanced stage dis-
ease, receive chemotherapy or targeted therapy as a
first line of treatment. Epidermal growth factor recep-
tor tyrosine kinase inhibitor (EGFR-TKI) and echino-
derm microtubule-associated protein-like 4-anaplastic
lymphoma kinase fusion tyrosine kinase inhibitor
(EML4-ALK-TKI) exert substantial therapeutic effects
in lung adenocarcinomas with specific commonly oc-
curring mutations [2–5]. Platinum-based treatment
regimens remain the standard of care recommended
by the lung cancer guidelines for squamous lung can-
cer or adenocarcinoma with undefined mutation status
[6]. Recently, studies [7, 8] have revealed that a
nedaplatin-based treatment regimen is associated with
a favorable response in patients with squamous cell
lung cancer. Platinum-based drugs are defined as
DNA adduct-forming agents that exert antineoplastic
effects by inducing the formation of double-stranded
DNA cross-links, thus resulting in irreversible DNA
damage [9]. Accumulating DNA damage eventually
leads to apoptosis [10, 11].
Nuclear-factor (NF)-E2-related factor 2 (NRF2) is a
core transcription factor involved in the cellular re-
sponse to oxidative stress [12]. Under basal conditions,
NRF2 forms a complex with Kelch-like ECH-associated
protein-1 (KEAP1), which is targeted for ubiquitination.
Upon exposure to stress or electrophilic regents, NRF2
evades the ubiquitination process and translocates from
the cytoplasm to the nucleus [13]. By binding to antioxi-
dant responsive element (ARE), NRF2 increases the
transcription of multiple cytoprotective enzymes [14]
such as heme oxygenase-1(HO1), NAD (P) H dehydro-
genase (quinone) 1 (NQO1), and glutamate-cysteine lig-
ase modifier (GCLM) [15].
In urethane-induced lung carcinogenesis model,
NRF2 activation suppresses tumorigenesis, but somatic
activation of NRF2 in cancer cells enhanced growth of
tumors [16]. Studies have demonstrated that NRF2 acti-
vation contributes to chemo-resistance [17–19] or
radio-resistance [20] in lung cancers. Investigators have
also focused on the relationship between NRF2 activity
and platinum treatment in NSCLC cell line [21, 22].
However, studies designed to observe and compare
NRF2 signaling response under different platinum
treatment are rarely reported [23]. In this study, we
sought to elucidate the role of NRF2 in platinum-based
chemotherapy for NSCLC, and we identified KEAP1
mutation as a key factor contributing to platinum
sensitivity.
Methods
Chemicals and cell culture
Unless otherwise stated, all chemicals were purchased
from Sigma-Aldrich (Shanghai, China). Antibodies against
NRF2 (ab62352) were purchased from Abcam; antibodies
against HO1 (#5853) and NQO1 (#3187) were purchased
from Cell Signaling Technology; and antibodies against
KEAP1 (10503-2-AP), GCLM (14241-1-AP), and β-actin
were purchased from Proteintech.
The A549 (human lung adenocarcinoma), H292 (human
mucoepidermoid carcinoma), H460 (human large cell lung
cancer), and SKMES-1 (human squamous lung cancer) cell
lines were obtained from the Cell Resource Center, Peking
Union Medical College. The cells were cultured in RPMI-
1640, with the exception of SKMES-1 cells, which were cul-
tured in MEM. All media were supplemented with 10 %
fetal bovine serum (GIBCO, NY, USA). No antibiotics were
added to the media.
Plasmid and siRNA design
The wild-type KEAP1 coding sequence (CDS) was cloned
into the pEnter shuttle plasmid. The Fast Mutagenesis sys-
tem (Transgene, Beijing, China) was used to introduce the









The small interfering RNAs used to silence NRF2 were:
Sense, GGUUGAGACUACCAUGGUUTT
Antisense, AACCAUGGUAGUCUCAACCTT
Transfection was conducted with Lipofectamine
2000 (Invitrogen) according to a previously published
method [24].
Real-time PCR analysis
Total messenger RNA (mRNA) was extracted from cells
using TRIzol according to the manufacturer’s protocol
(Takara, Japan). Seven hundred fifty-nanogram total mRNA
was used to synthesize first strand complementary DNA
(cDNA) using the cDNA synthesis kit (ThermoFisher
Scientific). Quantification reactions were performed with
the ABI 7900 HT platform. Each reaction consisted of 5 μl
SYBR Green/ROX qPCR Master Mix (ThermoFisher
Scientific), 1 μl cDNA, 1 μl 10 μM forward and reverse
primer mix, and 3 μl ddH2O. Cycling conditions were as
follows: 95 °C for 10 min and 40 cycles of 95 °C for 15 s
and 60 °C for 60 s. Cycle thresholds were calculated as the
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expression fold-changes according to the 2−△△CT algorithm.










Total RNA was extracted and used to synthesize the first
chain cDNA according to the procedure described in the
real-time PCR analysis description. cDNA was used as a
template to synthesize six segments of the KEAP1 gene
using the following cycling conditions: initial denaturing
step at 94 °C for 5 min followed by 30 cycles at 94 °C for
40 s, 60 °C for 40 s, and 72 °C for 55 s. Products were
separated on 1 % agarose gels, and bands were visualized
with ethidium bromide. The products were sequenced
using the ABI3730 XL DNA Analyzer (Applied Biosys-
tem Japan, Tokyo, Japan) and analyzed with Chromas





Fragment 2, forward CAGGTCAAGTACCAGGATG
Reverse GATGAGGGTCACCAGTTG
Fragment 3, forward ATCGGCATCGCCAACTTC
Reverse AGGTAGCTGAGCGACTGT
Fragment 4, forward CAGAAGTGCGAGATCCTG
Reverse GCTCTGGCTCATACCTCT
Fragment 5, forward GCCCTGGACTGTTACAAC
Reverse GTCTCTGTTTCCACATCGTA
Fragment 6, forward GCTGTCCTCAATCGTCTC
Reverse AGTTCTGCTGGTCAATCTG
NRF2 exon2, forward TCGTGATGGACTTGGAGCTG
Reverse AGCATCTGATTTGGGAATGTG
Sections were spliced together after manual inspection
and compared with the reference sequence with BLAST
to identify potential mutations.
Western blot analysis
Cytoplasm and nuclear protein were extracted by using
NE-PER™ Nuclear and Cytoplasmic Extraction Reagents
(ThermoFisher Scientific). For total protein extraction,
we used standard protocols for protein isolation and
antibody detection, as previously described [24, 25].
Cells were washed twice with ice-cold PBS and then
lysed with RIPA buffer. Each sample was denatured in
100 °C boiling water in the presence of SDS and DTT. A
total of 20 μg of protein from each sample was loaded
onto a 10 % SDS-PAGE gel for separation by electro-
phoresis. A tank system was used to transfer proteins
from gels to PVDF membranes. The membranes were
blocked with nonfat milk for 1 h and incubated with pri-
mary antibodies overnight. All primary antibodies were
used at a dilution of 1:1000, with the exception of anti-
β-actin (1:5000) and anti-NQO1 (1:3000). Blots were
sufficiently washed in 0.1 % Tris-buffered saline and
Tween20 (TBST) four to six times for at least 5 min per
wash. Washed membranes were incubated with second-
ary antibodies at a dilution of 1:5000 for 1 h at room
temperature. After incubation with secondary antibodies,
the membranes were washed three times for at least
5 min per wash. SuperSignal West Pico Chemilumines-
cent Substrate (ThermoFisher Scientific) was applied for
exposure using Syngene G: BOX F3 Fluorescence Im-
aging System. All images of the blots were processed in
Photoshop without gray value modification and spliced
in Microsoft PowerPoint.
Immunofluorescence staining
Immunofluorescence was performed as previously re-
ported with some modifications [26]. Cells were seeded
onto a 24-well plate until they reached a confluence of
50~60 % and were treated with the indicated reagents.
After treatment, cells were fixed in 4 % paraformalde-
hyde at 4 °C for 10 min. The cells were then washed in
PBS for 5 min and permeabilized and blocked with
0.1 % Triton X-100 and 1 % bovine serum albumin PBS
for 20 min. Cells were incubated with primary antibody
against HO1 at a dilution of 1:200 at 4 °C overnight. The
cells were then washed in PBS three times for 5 min per
wash. Cells were incubated with Alexa Fluor 488® sec-
ondary antibody (Invitrogen) at a dilution of 1:1000 for
1 h at room temperature. DAPI solution was added after
incubation with secondary antibody. Cells were washed
three times for 5 min per wash before imaging. Fluores-
cence images were captured using a Leica digital micro-
scope (Leica Microsystems, Wetzler, Germany). Images
were merged using Adobe Photoshop CS6, and no other
modifications were made.
Cytotoxic assay
Cellular proliferation was evaluated using a Cell Count Kit-
8 (CCK-8) with some modifications [27]. Lung cancer cell
lines were seeded onto 96-well plates for attachment for a
minimum of 12 h in a 37 °C incubator. Nedaplatin or cis-
platin dissolved in phosphate-buffered saline (PBS) was
added to the medium at a concentration gradient of 30–
150 μM. After 24 h of exposure, the medium was com-
pletely removed. Then, a medium with 10 % (v/v) CCK-8
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was added to each well. Absorbance at 490 nm was mea-
sured after a 2-h incubation at 37 °C. Cell survival was cal-
culated as the ratio between the treated group and control
groups. Ratios were graphed in line charts with Graphpad
Prism 6 software.
Public database analysis
Expression data from The Cancer Genome Atlas (TCGA)
squamous lung cancer patients was retrieved using the
package TCGA-Assembler (http://www.compgenome.org/
TCGA-Assembler/) in an R program. KEAP1 mutation
status was defined as previously described [28]. Specimens
with a confirmed KEAP1 mutation status were included
for evaluation of relative gene expression values.
Statistical methods
Parametric tests were used to evaluate data with a nor-
mal distribution. Non-parametric tests were used to
evaluate data with unknown distribution patterns.
mRNA fold-changes were compared using Student’s t
tests. Survival comparisons were conducted using paired
t tests. Comparisons between the mutant and wild-type
KEAP1 groups were conducted using Mann-Whitney
tests. Significance was set at P < 0.05.
Results
KEAP1 mutation status influenced the expression of NRF2
downstream target genes in cells exposed to platinum-
based treatment
KEAP1 is a key regulator of NRF2 function, and the role
of wild-type KEAP1 in negatively regulating NRF2 sig-
naling has been well characterized. We first sequenced
the KEAP1 gene in four NSCLC cell lines to identify po-
tential mutations and found that the A549 cell line har-
bors a G333C mutation within the first Kelch domain
(KLD) (Fig. 1a) and that the H460 cell line harbors a
D236H mutation in the intervention region (IVR)
(Fig. 1b). No KEAP1 mutations were identified in the
H292 and SKMES-1 cell lines. Sequencing of NRF2 exon
2 in the four NSCLC cell lines demonstrated that no
mutations existed in this locus. We then evaluated basal
protein levels of KEAP1 and components of the NRF2
signaling pathway in the four NSCLC cell lines. NRF2
protein in nuclear extracts and the proteins encoded by
the three genes downstream of NRF2, HO1, NQO1, and
GCLM were more highly expressed in A549 and H460
cells than in H292 and SKMES-1 cells (Fig. 1d).
To profile the expression of NRF2 signaling pathway
components in response to platinum treatment, the four
NSCLC cell lines (H292, SKMES-1, A549, and H460)
were treated with 30 μM nedaplatin or 30 μM cisplatin
for 24 h. Total RNA from each group was extracted, and
HO1, NQO1, and GCLM gene expression levels were
assessed with real-time PCR. In the wild-type KEAP1
cell lines H292 (Fig. 2a) and SKMES-1 (Fig. 2b), neda-
platin and cisplatin slightly enhanced the expression of
NRF2 downstream target genes after 24 h of treatment.
In the mutant KEAP1 cell line A549 (Fig. 2c, *p < 0.01,
**p < 0.05) and H460 (Fig. 2d, *p < 0.01, **p < 0.05), neda-
platin induced a weak but significant increase in three
downstream gene expression. Cisplatin treatment, how-
ever, significantly enhanced HO1, NQO1, and GCLM
expression in both A549 and H460 cell lines after 24 h
of treatment.
To evaluate protein levels, the four cell lines were
treated with 30 μM nedaplatin or 30 μM cisplatin for 3
or 24 h. Total proteins were extracted, and HO1,
NQO1, GCLM protein expression was evaluated by
using western blot analysis. In the wild-type KEAP1
H292 and SKMES-1 cell lines (Fig. 2e, f ), a mild increase
or no change of NQO1 and HO1 protein was observed
after 3- or 24-h treatment with either platinum-based
drug. In the mutant KEAP1 cell lines A549 (Fig. 2g) and
H460 (Fig. 2h), a mild increase or no change was ob-
served in NQO1 and HO1 protein levels after nedaplatin
treatment, whereas the expression of these proteins was
substantially enhanced after 24 h of treatment with
cisplatin.
The results of immunofluorescence analysis of HO1
protein expression were consistent with the results of
the western blot analysis. Over a 24-h treatment period,
30 μM nedaplatin or cisplatin induced a mild increase in
HO1 protein expression in H292 and SKMES-1 cells
(Fig. 2i). In the A549 and H460 cell lines (Fig. 2j), both
platinum-based drugs enhanced the expression of HO1
to a greater degree over the same time period.
KEAP1 mutations modified NRF2 signaling and influenced
platinum sensitivity
To investigate the impact of KEAP1 mutations status on
NRF2 signaling, the KEAP1 CDS was cloned into the
pEnter vector and transfected into the NSCLC cell lines.
In the mutant KEAP1 cell lines A549 (Fig. 3a, b, *p <
0.001, **p < 0.05) and H460 (Fig. 3e, f, *p < 0.001), consti-
tutive expression of wild-type KEAP1 over a 72-h period
reduced the expression of the NRF2 downstream target
genes HO1, NQO1, and GCLM at the mRNA and pro-
tein levels. Overexpression of wild-type KEAP1 sensi-
tized A549 cells (Fig. 3c, d, paired t test p = 0.0118 for
nedaplatin, paired t test p = 0.0046 for cisplatin) and
H460 cells (Fig. 3g, h, paired t test p = 0.0089 for neda-
platin, paired t test p = 0.0134 for cisplatin) to nedaplatin
and cisplatin over a 24-h treatment period.
Next, we introduced the G333C and D236H mutations
into the KEAP1 pEnter construct. The mRNA expres-
sion levels of the NRF2-associated genes HO1, NQO1,
and GCLM were significantly elevated in H292 cells
(Fig. 4a, *p < 0.001, **p < 0.05) and SKMES-1 cells
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(Fig. 4e, *p < 0.001, **p < 0.05) transfected with the mu-
tant KEAP1 construct. An identical trend was observed
at the protein level (Fig. 4b, f ). Transfection of the mu-
tant KEAP1 plasmid significantly increased survival in
H292 cells (Fig. 4c, d, *p < 0.001, **p < 0.05) and SKMES-
1 (Fig. 4g, h, *p < 0.001) treated with 60 μM cisplatin or
nedaplatin.
NRF2 activity altered downstream gene expression and
influenced platinum sensitivity
To assess the effects of NRF2 expression on NSCLC cells
exposed to platinum-based drugs, we designed a small
interfering RNA (siRNA) construct targeting NRF2
mRNA to inhibit NRF2 activity. In the wild-type KEAP1
cell lines H292 (Fig. 5a, b, *p < 0.001, **p < 0.05) and
SKMES-1 (Fig. 5e, f, *p < 0.001, **p < 0.05), siRNA trans-
fection over a 72-h period reduced the expression of
NRF2 and its downstream targets HO1, NQO1, and
GCLM at the mRNA and protein levels. Pretreatment
with siRNA targeting NRF2 increased sensitivity to neda-
platin and cisplatin in H292 cells (Fig. 5c, d, paired t test
p = 0.0042 for nedaplatin, paired t test p = 0.0053 for
cisplatin) and SKMES-1 (Fig. 5g, h, paired t test p = 0.0116
for nedaplatin, paired t test p = 0.0057 for cisplatin) over a
24-h treatment period.
In addition, NSCLC cell lines were treated with t-BHQ, a
specific activator of NRF2. In the wild-type KEAP1 NSCLC
cell lines H292 (Fig. 6a, b, *p < 0.001, **p < 0.05) and
SKMES-1 (Fig. 6e, f, *p < 0.001, **p < 0.05), administration
of the NRF2 activator over a 24-h period significantly
increased the expression of the NRF2 downstream genes
HO1, NQO1, and GCLM at the mRNA and protein levels.
Pretreatment with 60 μm t-BHQ conferred chemo-
resistance to nedaplatin and cisplatin in H292 cells (Fig. 6c,
d, paired t test p = 0.0089 for nedaplatin, paired t test p =
0.0105 for cisplatin) and in SKMES-1 cells (Fig. 6g, h,
paired t test p = 0.0218 for nedaplatin, paired t test p =
0.0057 for cisplatin) over a 24-h treatment period.
KEAP1 mutation enhanced NRF2 signals expression in
NSCLC patients
A total of 100 individuals diagnosed with NSCLC were se-
lected from the TCGA group for analysis. KEAP1 mutation
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Fig. 1 Identification of KEAP1 mutations and basal expression levels of NRF2-regulated genes in NSCLC. Sequencing of the KEAP1 gene led to the
identification of G333C mutation in A549 cells (a) and the D236H mutation in H460 cells (b). The arrow indicates the mutant peak. c Characteristics of
the four NSCLC cell lines and a description of the KEAP1 mutations. NA, no mutant domain. d Basal expression of KEAP1, NRF2, and NRF2-regulated
genes in the four NSCLC cell lines
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Fig. 2 Comparison of NRF2-regulated gene expression in NSCLC cells exposed to platinum-based drugs. a, b The levels of HO1, NQO1, and GCLM
mRNA expression in H292 and SKMES-1 cells exposed to 30 μM nedaplatin or cisplatin for 24 h. c, d The expression levels of HO1, NQO1, and
GCLM mRNA in A549 and SKMES-1 cells exposed to 30 μM nedaplatin or cisplatin for 24 h. Comparison was conducted between 24-h points and
control group by using Student’s tests. The results are presented as the mean ± SEM. *p < 0.01, **p < 0.05. e, f The levels of HO1, NQO1, and GCLM
protein expression in H292 and SKMES-1 cells exposed to 30 μM nedaplatin or cisplatin for 3 or 24 h. g, h The levels of HO1, NQO1, and GCLM
protein expression in A549 and H460 cells exposed to 30 μM nedaplatin or cisplatin for 3 or 24 h. i Immunofluorescence staining of HO1 in H292
(upper panel) and SKMES-1 (lower panel) cells exposed to 30 μM nedaplatin or cisplatin over a 24-h treatment period. j Immunofluorescence staining of
HO1 in H460 (upper panel) and A549 (lower panel) exposed to 30 μM nedaplatin or cisplatin over a 24-h treatment period
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that 86 patients harbored the wild-type KEAP1 allele, and
16 patients harbored a KEAP1 mutation. Gene expression
data from patients with mutant or wild-type KEAP1 were
used to generate a scatter plot diagram. No significant dif-
ferences in the mRNA expression levels of NRF2 (Fig. 7a
Mann-Whitney test p = 0.193) and KEAP1 (Fig. 7b Mann-
Whitney test p = 0.265) were observed between the mu-
tated patients with mutant KEAP1 cases and with wild-type
KEAP1. However, expression levels of the NRF2 down-
stream target genes HO1 (Fig. 7c Mann-Whitney test p =
0.0083), NQO1 (Fig. 7d Mann-Whitney test p < 0.0001),
and GCLM (Fig. 7e Mann-Whitney test p < 0.0001) were
significantly enhanced in patients with mutant KEAP1
cases compared with those with wild-type KEAP1.
Discussion
A large genomic study has demonstrated that multiple
oncogenic and tumor suppressor pathways are in-
volved in the initiation and progression of lung cancer
[29]. In addition to the well-known oncogenic path-
ways, such as those mediated by retrovirus-associated
DNA sequences (RAS), epidermal growth factor re-
ceptor (EGFR), and anaplastic lymphoma kinase






















































































































































Fig. 3 KEAP1 overexpression inhibits NRF2 signaling and increases chemosensitivity to nedaplatin or cisplatin in KEAP1-mutant cells. a, b mRNA
and protein levels of NRF2-regulated genes in A549 cells overexpressing wild-type KEAP1. c, d KEAP1 overexpression modified the sensitivity of
A549 cells to platinum-based drugs. e, f mRNA and protein levels of NRF2 downstream genes in H460 cells overexpressing wild-type KEAP1. g, h
KEAP1 overexpression modified the sensitivity of H460 cells to platinum-based drugs. The results are presented as the mean ± SEM. *p < 0.001,
**p < 0.05. Vec vector
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identified, such as those mediated by NOTCH [30, 31]
and DACH1 [26, 32]. Targeted drugs already serve as
a first-line therapy for NSCLC patients with specific
mutations. However, for the many NSCLC patients
with an unknown mutation status or with no gene
mutations, platinum-based regimens remain the
standard of care proposed by NCCN guideline. Previ-
ous studies [20, 33] have revealed that NRF2 and its
downstream genes play pivotal protective roles in
NSCLC chemotherapy. A recent genomic analysis has
revealed that disruptions in the KEAP1/NRF2 pathway






















































































































































Fig. 4 KEAP1 mutations activate NRF2 signaling and confer chemo-resistance. a, b KEAP1 with the G333C or D236H mutations induced the expression
of NRF2 downstream target genes at the mRNA and protein levels in H292 cells. c, d KEAP1 with the G333C or D236H mutations increased cell survival
in H292 cells exposed to 60-μm platinum-based drugs. e, f KEAP1 with the G333C or D236H mutation induced the expression of NRF2-associated
genes at the mRNA and protein levels in SKMES-1 cells. g, h KEAP1 with the G333C or D236H mutation increased cell survival in SKMES-1 cells exposed
to 60-μm platinum-based drugs. The results are presented as the mean ± SEM. *p < 0.001, **p < 0.05. Vec vector
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patients [28]. KEAP1 mutations were more common
in smoked NSCLC. Research by Takahashi et al. [34]
demonstrated all four KEAP1 mutated lung cancer pa-
tients were heavy smoker with a mean pack year value
of 79.0, while no KEAP1 mutation was detected in no-
smoked patients. Platinum-induced DNA damage and
cellular response to stress might be associated with
the efficacy of chemotherapy and might contribute to
resistance [10, 12, 35].
Functional KEAP1 represses NRF2 activity by recruit-
ing the NRF2 protein to the actin cytoskeleton [36]. Se-
quencing experiments revealed that the A549 cell line
harbors a mutation (glycine 333 to cysteine) in the Kelch
domain and that the H460 cell line harbors a mutation
(aspartic acid 236 to histidine) in the intervention region
of KEAP1. No mutations in exon 2 of the NRF2 gene,
the site associated with most NRF2 mutations [37], have
been identified in sequencing analysis. We observed in-
creased basal levels of NRF2 downstream target genes in
the NSCLC cell lines harboring KEAP1 mutations com-
pared with the wild-type KEAP1 NSCLC cell lines. Inter-
estingly, an increased protein level of cytoplasm NRF2 in
squamous cell lung cancer cell line SKMES-1 was ob-



















































































































































Fig. 5 siRNA inhibited NRF2 signaling and increased chemosensitivity to platinum-based drugs. a, b siRNA knockdown of NRF2 reduced the expression of
NRF2 and NRF2-regulated genes at the mRNA and protein levels in H292 cells. c, d siRNA increased the sensitivity of H292 cells to
platinum-based drugs. e, f siRNA targeting NRF2 reduced the expression of NRF2 and NRF2-associated genes at the mRNA and protein
levels in SKMES-1 cells. g, h siRNA knockdown of NRF2 increased platinum sensitivity in SKMES-1 cells. The results are presented as the
mean ± SEM. *p < 0.001, **p < 0.05. Vec vector
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lead to increased NRF2 nuclear accumulation and ex-
pression of NRF2 downstream target genes, suggesting
that NRF2 function is tightly regulated by wild-type
KEAP1. Our findings provide a visual profile of the
functional and aberrant KEAP1-NRF2 interactions ob-
served in NSCLC.
After exposure to cisplatin, the KEAP1 mutant cell
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Fig. 6 t-BHQ activated NRF2 signaling and conferred chemo-resistance to platinum-based drugs. a, b t-BHQ induced the expression of NRF2 and
NRF2-regulated genes at the mRNA and protein levels in H292 cells. c, d t-BHQ conferred chemo-resistance to platinum-based drugs in H292
cells. e, f t-BHQ induced the expression of NRF2 and NRF2-regulated genes at the mRNA and protein levels in SKMES-1 cells. g, h t-BHQ conferred
chemo-resistance to platinum-based drugs in SKMES-1 cells. The results are presented as the mean ± SEM. *p < 0.001, **p < 0.05. Vec vector
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levels of NRF2 signaling, whereas when the KEAP1
wild-type cell lines H292 and SKMES-1 exhibited no
changes or only mild changes. Cisplatin is a weak in-
ducer of ARE in the MCF-7 human breast cancer cell
line (without KEAP1 mutation [38]) and induces a 1.3-
fold change in ARE expression levels after 24 h of expos-
ure [15], consistently with our observations in wild-type
KEAP1 NSCLC cells. Interestingly, in KEAP1 mutant
cell lines, two platinum drugs induced different level of
increasing extents of NRF2 signaling. That is less than
2.5-fold induction for NRF2 by nedaplatin and more
than 3.5-folds by cisplatin were observed. This
phenomenon was mostly seen on HO1 gene. HO1 blots
in Fig. 2g, h demonstrated that nedaplatin induced lower
while cisplatin induced higher elevation of HO1 gene in
A549 and H460. Reactive oxygen species (ROS) play a
role in cisplatin induced and activated by a variety of sig-
nals [39, 40]. KEAP1 perceives cellular ROS levels via its
multiple amino acid domains [38, 41, 42]. KEAP1 muta-
tions disrupt the interaction between KEAP1 and NRF2
[22]; however, the kinetics of this interaction in KEAP1
mutant cells exposed to cisplatin have not previously
been described. Our findings suggest that NRF2 signal-
ing is upregulated in NSCLC cells harboring KEAP1
mutations.
However, nedaplatin induces only weak activation or
no activation of NRF2 signaling. The antineoplastic ac-
tivity of nedaplatin, a cisplatin derivate developed in
1983 [43], might be mediated by mechanisms distinct
from those of p53-dependent early apoptosis [44]. Sev-
eral studies have demonstrated that a nedaplatin-based
treatment regimen [45–47] for squamous cell lung can-
cer is superior to a cisplatin or carboplatin-based regi-
men [48]. Our work provides a potential rationale for
nedaplatin as the optimal choice for NSCLC patients
with KEAP1 mutations. Platinum-based drugs are cap-
able of binding DNA [49], explaining why we observed a
decrease in the expression of NRF2 downstream genes
during early phases (3 h) of platinum exposure in wild-
type KEAP1 H292 cell line.
An early study by Devling et al. [50] has revealed that
inhibition of KEAP1 function markedly enhances en-
dogenous levels of NRF2. Our results demonstrated that
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Fig. 7 Comparison of NRF2-associated genes mRNA between KEAP1-wt and KEAP1-mut cases in squamous lung cancer. a NRF2 mRNA expression
levels in KEAP1-wt and KEAP1-mut cases. b KEAP1 mRNA expression levels in KEAP1-wt and KEAP1-mut cases. c HO1 mRNA levels between
KEAP1-wt and KEAP1-mut cases. d NQO1 mRNA levels in KEAP1-wt and KEAP1-mut cases. e GCLM mRNA expression levels in KEAP1-wt and
KEAP1-mut cases. f Schematic diagram of wild-type (left) and mutant KEAP1 protein (right) function. Mutant KEAP1 was predicted to exhibit
an attenuated unity. The increased nuclear accumulation and transcriptional activity of NRF2 upregulate the expression of cytoprotective
genes such as HO1, NQO1, and GCLM, thereby leading to cancer cell chemo-resistance. BTB, broad complex, tramtrack, and Bric à brac, IVR
intervention region, wt wild type, mut mutation. The results are presented as the median ± quartile
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NRF2 signaling and sensitized A549 and H460 cells to
platinum-based treatment. In addition, expression of
G333C and D236H mutant KEAP1 increased the expres-
sion of NRF2 downstream genes at the mRNA and pro-
tein levels and resulted in increased cell survival after
exposure to platinum-based drugs. Most KEAP1 muta-
tions enhance the nuclear localization of NRF2, thereby
leading to the constitutive activation of downstream
gene expression [51]. Although nedaplatin induced lower
activation of NRF2 signal in KEAP1 mutant cell line, its
sensitivity can be influenced by intervention on NRF2
activity. As NRF2 upregulate a series of detoxification
genes and protect cancer cells against insults, our results
demonstrated that the sensitivity of nedaplatin may be
influenced by other NRF2 downstream genes, including
but not limited to AKR1C3, GST, and PSAT1 [52]. In
addition, in Fig. 4c, d, Keap1 mutation in H292 cell line
conferred indeed less resistance to nedaplatin than cis-
platin. But this superiority for nedaplatin was not that
significant in SKMES-1 cells (Fig. 4g, h). The underneath
mechanism requires validation. In summary, we demon-
strated that KEAP1 mutations influence NRF2 signaling
and platinum sensitivity in NSCLC cells.
NRF2 activity is involved in chemosensitivity in breast
cancer [20] and ovarian cancer [33]. Clinical evidence
[53, 54] has also suggested that NRF2 signaling confers
chemo-resistance in NSCLC. We found that siRNA
knockdown of NRF2 or NRF2 activation significantly dis-
rupted NRF2 signaling in vitro and led to sensitization or
resistance of NSCLC cells to platinum-based drugs. It
demonstrated again that NRF2 signals had a significant
impact on platinum sensitivity in H292. We expected to
see that NRF2 activity have no impact on nedaplatin sensi-
tivity, but repeated experiment demonstrated a minor but
significant effect of NRF2 on nedaplatin sensitivity (paired
t test p value 0.0116). This effect was also observed in
Fig. 6g (paired t test p value 0.0218). We speculated that
under siRNA intervention or activator treatment, some
other pathways such as NF-kappa B and BACH1 are com-
pensatorily involved in the process [55]. Our work pro-
vides some new insights into the relationship between
NRF2 signaling and platinum-based chemotherapy.
To confirm the significance of KEAP1 mutation in
vivo, we evaluated public gene expression data from
the publically available TCGA consortium. As ex-
pected, KEAP1 mutation did not significantly change
alter the mRNA expression of NRF2 and KEAP1. How-
ever, mRNA levels of NRF2 downstream target genes
were significantly higher in patients with KEAP1 muta-
tions compared with patients with wild-type KEAP1,
suggesting that KEAP1 and NRF2 interact primarily at
the protein level and that KEAP1 mutations strongly
affect NRF2 signaling (Fig. 7f ). The association of
clinical response with these mutations was not well
defined before. One mentioned study evaluated the im-
pact of KEAP1 alteration on NSCLC patients’ survival
[34]. In this study, KEAP1 mutation predicted a worse
overall survival. As to disease-free survival, this study
demonstrated a vague trend toward significance.
Conclusions
In summary, the mRNA and protein expression profile
of NRF2 and components of the NRF2-associated genes
in four NSCLC cell lines were characterized and their
responses to platinum-based therapies were analyzed. A
causative effect of KEAP1-NRF2 signaling on platinum-
based treatment was defined by engineered expressing
either wild-type or mutant KEAP1 and knocking-down
or activating NRF2. It is reasonable to hypothesize that
KEAP1/NRF2 plays a key role in the cellular response to
platinum chemotherapy in NSCLC and that KEAP1
could be explored as a specific biomarker for predicting
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